CNS Pharmaceuticals, Inc.
CNSP
$6.12
-$0.42-6.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.47% | -35.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.45% | 35.55% | |||
| Operating Income | 44.45% | -35.55% | |||
| Income Before Tax | 44.78% | -35.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.78% | -35.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.78% | -35.41% | |||
| EBIT | 44.45% | -35.55% | |||
| EBITDA | 44.47% | -35.56% | |||
| EPS Basic | 66.10% | 46.66% | |||
| Normalized Basic EPS | 66.10% | 46.66% | |||
| EPS Diluted | 66.14% | 46.67% | |||
| Normalized Diluted EPS | 66.10% | 46.66% | |||
| Average Basic Shares Outstanding | 62.90% | 153.85% | |||
| Average Diluted Shares Outstanding | 62.90% | 153.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||